Antiangiogenic drugs in ovarian cancer
Open Access
- 11 November 2008
- journal article
- review article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 100 (1), 1-7
- https://doi.org/10.1038/sj.bjc.6604767
Abstract
Ovarian cancer continues to be a major cause of morbidity and mortality in women. Antiangiogenic treatments have emerged as a promising strategy to treat ovarian cancer. This article reviews the rationale supporting the use of antiangiogenic treatments in ovarian cancer, the clinical development of this group of drugs and the toxicities specific to this modality of treatment.Keywords
This publication has 63 references indexed in Scilit:
- Modes of resistance to anti-angiogenic therapyNature Reviews Cancer, 2008
- Circulating endothelial cells in oncology: pitfalls and promisesBritish Journal of Cancer, 2008
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerNew England Journal of Medicine, 2007
- Tumour vascularization: sprouting angiogenesis and beyondCancer and Metastasis Reviews, 2007
- The integrinsGenome Biology, 2007
- Genes that Distinguish Physiological and Pathological AngiogenesisCancer Cell, 2007
- DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agentsBritish Journal of Cancer, 2007
- AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma PatientsCancer Cell, 2007
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisCell, 1996
- Induction of angiogenesis during the transition from hyperplasia to neoplasiaNature, 1989